Unknown

Dataset Information

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.


ABSTRACT:

Background

Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma.

Methods

Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretino

SUBMITTER: Yu AL 

PROVIDER: S-EPMC3086629 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature